Biovica continues to increase 12m rolling IVD test sales in Q4 of SEK 0.93m (314% rolling 12m) and total sales of SEK 2.3m after adding ROU sales (test and services). Biovica is also progressing with a guaranteed rights issue at SEK 80m (gross) and advancing the sales outlook based on Tempus AI in the Oncology segment, with a major partner in the IDN segment.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/